Comparative Study Between Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women at or Beyond Completed 41 Weeks /
Elsayed Fekry Elsayed Omran,
Comparative Study Between Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women at or Beyond Completed 41 Weeks / دراسة الفرق بين إعطاء عقار الميزوبروستول بالفم أو بالمهبل لتحريض الولادة في السيدات اللاتي لم ينجبن من قبل وأتممن 41 أسبوع من الحمل / By Elsayed Fekry Elsayed Omran; Under Supervision of DR. Heba Aly El Sawah, DR. Marwa Fouad Sharaf, DR. Mahmoud Ahmed Ismail AbdElhameed - 73 pages : illustrations ; 25 cm. + CD.
Thesis (M.Sc.) -Cairo University, 2023.
Bibliography: pages 63-73.
Background: Although, vaginal application of misoprostol has been
validated as a reasonable mean of induction, there is a patient resistance to
digital examination and there is a risk of ascending infection. So, oral
administration of misoprostol for labor induction was tried.
Aim and objectives: To compare efficacy and safety of vaginal
misoprostol with oral misoprostol for induction of labor in
nulliparouspregnantwomenatorbeyondcompleted41weeks.
Subjects and methods: Eighty nulliparous pregnant women who were
candidate for labor induction at or beyond completed 41 weeks divided into
two groups: (Group 1):40 pregnant women who received vaginal
misoprostol in a dose of 25μg and repeated every 6 hours if no response
was achieved with a maximum of 4 doses, (Group 2):40 pregnant women
who received oral misoprostol in a dose of 25μg and repeated every 6 hours
if no response was achieved with a maximum of 4 doses.
Results: There was no statistically significant difference between oral&
vaginal misoprostol regarding induction to active stage of labor, induction
to delivery interval, cesarean deliveries, number of doses needed, maternal
or neonatal complications. On the other hand, oxytocin augmentation was
significantly lower in the vaginal group.
Conclusion: 25 mg orally administered misoprostol is similarly effective
& safe as 25 mg vaginal misoprostol to induce labor in nulliparous women
with an unripe cervix at or beyond completed 41weeks. كانت الحاجة لزيادة تحفيز المخاض باستخدام الأوكسيتوسين أعلى بشكل يعتد به في مجموعة الميزوبروستول الفموى بالمقارنة مع مجموعة الميزوبروستول المهبلى. إن تناول 25 ملغ من الميزوبروستول عن طريق الفم فعالة وآمنة بشكل مشابه مثل تناول 25 ملغ من الميزوبروستول عن طريق المهبل للحث على المخاض عند النساء اللاتي لم ينجبن من قبل وأتممن 41 أسبوعًا من الحمل. ومع ذلك، وُجد أن الحاجة إلى تحفيز المخاض باستخدام الأوكسيتوسين أعلى لدى النساء اللائي استخدمن الميزوبروستول الفموي
Text in English and abstract in Arabic & English.
Obstetrics and Gynecology
Vaginal misoprostol Oral misoprostol Labor induction
618.1
Comparative Study Between Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women at or Beyond Completed 41 Weeks / دراسة الفرق بين إعطاء عقار الميزوبروستول بالفم أو بالمهبل لتحريض الولادة في السيدات اللاتي لم ينجبن من قبل وأتممن 41 أسبوع من الحمل / By Elsayed Fekry Elsayed Omran; Under Supervision of DR. Heba Aly El Sawah, DR. Marwa Fouad Sharaf, DR. Mahmoud Ahmed Ismail AbdElhameed - 73 pages : illustrations ; 25 cm. + CD.
Thesis (M.Sc.) -Cairo University, 2023.
Bibliography: pages 63-73.
Background: Although, vaginal application of misoprostol has been
validated as a reasonable mean of induction, there is a patient resistance to
digital examination and there is a risk of ascending infection. So, oral
administration of misoprostol for labor induction was tried.
Aim and objectives: To compare efficacy and safety of vaginal
misoprostol with oral misoprostol for induction of labor in
nulliparouspregnantwomenatorbeyondcompleted41weeks.
Subjects and methods: Eighty nulliparous pregnant women who were
candidate for labor induction at or beyond completed 41 weeks divided into
two groups: (Group 1):40 pregnant women who received vaginal
misoprostol in a dose of 25μg and repeated every 6 hours if no response
was achieved with a maximum of 4 doses, (Group 2):40 pregnant women
who received oral misoprostol in a dose of 25μg and repeated every 6 hours
if no response was achieved with a maximum of 4 doses.
Results: There was no statistically significant difference between oral&
vaginal misoprostol regarding induction to active stage of labor, induction
to delivery interval, cesarean deliveries, number of doses needed, maternal
or neonatal complications. On the other hand, oxytocin augmentation was
significantly lower in the vaginal group.
Conclusion: 25 mg orally administered misoprostol is similarly effective
& safe as 25 mg vaginal misoprostol to induce labor in nulliparous women
with an unripe cervix at or beyond completed 41weeks. كانت الحاجة لزيادة تحفيز المخاض باستخدام الأوكسيتوسين أعلى بشكل يعتد به في مجموعة الميزوبروستول الفموى بالمقارنة مع مجموعة الميزوبروستول المهبلى. إن تناول 25 ملغ من الميزوبروستول عن طريق الفم فعالة وآمنة بشكل مشابه مثل تناول 25 ملغ من الميزوبروستول عن طريق المهبل للحث على المخاض عند النساء اللاتي لم ينجبن من قبل وأتممن 41 أسبوعًا من الحمل. ومع ذلك، وُجد أن الحاجة إلى تحفيز المخاض باستخدام الأوكسيتوسين أعلى لدى النساء اللائي استخدمن الميزوبروستول الفموي
Text in English and abstract in Arabic & English.
Obstetrics and Gynecology
Vaginal misoprostol Oral misoprostol Labor induction
618.1